AR023058A1 - Derivados del tiazol, un procedimiento para su obtencion, composiciones farmaceuticas que los comprenden y el empleo de los mismos para la preparacion demedicamentos - Google Patents

Derivados del tiazol, un procedimiento para su obtencion, composiciones farmaceuticas que los comprenden y el empleo de los mismos para la preparacion demedicamentos

Info

Publication number
AR023058A1
AR023058A1 ARP990105306A ARP990105306A AR023058A1 AR 023058 A1 AR023058 A1 AR 023058A1 AR P990105306 A ARP990105306 A AR P990105306A AR P990105306 A ARP990105306 A AR P990105306A AR 023058 A1 AR023058 A1 AR 023058A1
Authority
AR
Argentina
Prior art keywords
cell
procedure
obtaining
preparation
pharmaceutical compositions
Prior art date
Application number
ARP990105306A
Other languages
English (en)
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR023058A1 publication Critical patent/AR023058A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C07D277/48—Acylated amino or imino radicals by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof, e.g. carbonylguanidines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Derivados de tiazol que comprenden compuestos de formula (1), así como las sales y ésteres farmacéuticamente aceptables de los mismos, en donde R1, R2 y R3tienen el significado dado en la memoria. Inhiben la union de las proteínas adhesivas a la superficie de diferentes tipos de células y en consecuencia influyensobre las interacciones célula-célula y célula-matriz. También se describen composiciones farmacéuticas para el control o prevencion de neoplasmas, metástasisde tumores, crecimiento tumoral, osteoporosis, enfermedad de Paget, retinopatía diabética, degeneracion macular, restenosis después de una intervencionvascular, psoriasis, artitris, fibrosis, deficiencia renal, así como infecciones causadas por virus, bacterias u hongos, un procedimiento para su obtencion yel empleo de los mismos para la preparacion de medicamentos.
ARP990105306A 1998-10-22 1999-10-20 Derivados del tiazol, un procedimiento para su obtencion, composiciones farmaceuticas que los comprenden y el empleo de los mismos para la preparacion demedicamentos AR023058A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP98119985 1998-10-22

Publications (1)

Publication Number Publication Date
AR023058A1 true AR023058A1 (es) 2002-09-04

Family

ID=8232838

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP990105306A AR023058A1 (es) 1998-10-22 1999-10-20 Derivados del tiazol, un procedimiento para su obtencion, composiciones farmaceuticas que los comprenden y el empleo de los mismos para la preparacion demedicamentos

Country Status (31)

Country Link
US (1) US6297266B1 (es)
EP (1) EP1123283B1 (es)
JP (1) JP3530137B2 (es)
KR (1) KR100469219B1 (es)
CN (1) CN1211375C (es)
AR (1) AR023058A1 (es)
AT (1) ATE266012T1 (es)
AU (1) AU760219B2 (es)
BR (1) BR9914666A (es)
CA (1) CA2347741C (es)
CO (1) CO5150186A1 (es)
CZ (1) CZ20011395A3 (es)
DE (1) DE69917058T2 (es)
DK (1) DK1123283T3 (es)
ES (1) ES2221482T3 (es)
HK (1) HK1047281A1 (es)
HR (1) HRP20010275A2 (es)
HU (1) HUP0104202A3 (es)
ID (1) ID28356A (es)
IL (1) IL142090A0 (es)
MA (1) MA26756A1 (es)
NO (1) NO20011908L (es)
NZ (1) NZ510676A (es)
PE (1) PE20001116A1 (es)
PL (1) PL347427A1 (es)
PT (1) PT1123283E (es)
RU (1) RU2214404C2 (es)
TR (1) TR200101115T2 (es)
WO (1) WO2000024724A1 (es)
YU (1) YU29201A (es)
ZA (1) ZA200102653B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7125875B2 (en) 1999-04-15 2006-10-24 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
MXPA01010292A (es) 1999-04-15 2002-10-23 Squibb Bristol Myers Co Inhibidores ciclicos de la proteina tirosina cinasa.
KR100766158B1 (ko) * 2000-01-19 2007-10-10 알테온 인크. 티아졸, 이미다졸 및 옥사졸 화합물, 및 단백질 노화와관련된 장애의 치료
JP5153047B2 (ja) 2000-08-17 2013-02-27 ギグオプティックス， インコーポレイテッド 電気光学用途用の最新ｎｌｏ物質の設計および合成
CA2433018A1 (en) 2000-12-21 2002-06-27 Joel C. Barrish Thiazolyl inhibitors of tec family tyrosine kinases
EP1797084A1 (en) * 2004-09-20 2007-06-20 4Sc Ag NOVEL HETEROCYCLIC NF-kB INHIBITORS
UA103319C2 (en) 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
WO2010012793A1 (en) * 2008-08-01 2010-02-04 Bayer Cropscience Sa Fungicide aminothiazole derivatives

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL95548A0 (en) * 1989-09-15 1991-06-30 Fujisawa Pharmaceutical Co Thiazole derivatives,processes for the preparation thereof and pharmaceutical composition containing the same
CA2037153A1 (en) * 1990-03-09 1991-09-10 Leo Alig Acetic acid derivatives
US5273982A (en) 1990-03-09 1993-12-28 Hoffmann-La Roche Inc. Acetic acid derivatives
US6306840B1 (en) * 1995-01-23 2001-10-23 Biogen, Inc. Cell adhesion inhibitors
JPH0987237A (ja) * 1995-09-21 1997-03-31 Kyowa Hakko Kogyo Co Ltd 芳香族誘導体
EP0928793B1 (en) * 1998-01-02 2002-05-15 F. Hoffmann-La Roche Ag Thiazole derivatives
SI0928790T1 (en) * 1998-01-02 2003-06-30 F. Hoffmann-La Roche Ag Thiazole derivatives

Also Published As

Publication number Publication date
WO2000024724A1 (en) 2000-05-04
EP1123283B1 (en) 2004-05-06
CN1211375C (zh) 2005-07-20
DE69917058T2 (de) 2005-04-07
ID28356A (id) 2001-05-17
US6297266B1 (en) 2001-10-02
DE69917058D1 (de) 2004-06-09
CA2347741A1 (en) 2000-05-04
BR9914666A (pt) 2001-07-17
CO5150186A1 (es) 2002-04-29
ATE266012T1 (de) 2004-05-15
PL347427A1 (en) 2002-04-08
JP3530137B2 (ja) 2004-05-24
CZ20011395A3 (cs) 2001-08-15
NO20011908D0 (no) 2001-04-18
YU29201A (sh) 2005-06-10
HRP20010275A2 (en) 2002-06-30
RU2214404C2 (ru) 2003-10-20
CN1359381A (zh) 2002-07-17
CA2347741C (en) 2006-12-12
KR20010080243A (ko) 2001-08-22
IL142090A0 (en) 2002-03-10
NZ510676A (en) 2003-06-30
AU760219B2 (en) 2003-05-08
KR100469219B1 (ko) 2005-02-07
PT1123283E (pt) 2004-09-30
ZA200102653B (en) 2002-07-01
DK1123283T3 (da) 2004-09-13
NO20011908L (no) 2001-04-18
EP1123283A1 (en) 2001-08-16
JP2002528442A (ja) 2002-09-03
HUP0104202A2 (hu) 2002-03-28
AU1151900A (en) 2000-05-15
HK1047281A1 (zh) 2003-02-14
ES2221482T3 (es) 2004-12-16
MA26756A1 (fr) 2004-12-20
PE20001116A1 (es) 2000-10-27
TR200101115T2 (tr) 2002-01-21
HUP0104202A3 (en) 2003-12-29

Similar Documents

Publication Publication Date Title
AR024703A1 (es) Benzazepinonas y quinazolinas
AR023401A1 (es) Derivados de 1,4-benzotiazepina-1,1-dioxido sustituidos con restos de azucar, procedimientos para su preparacion, medicamentos que contienen estoscompuestos, y su empleo para preparar un medicamento
GT200000183A (es) Aminoacidos biciclicos como agentes farmaceuticos.
BR112021025928A2 (pt) Métodos de preparação de ácido bempedoico e composições do mesmo
BR0317283A (pt) Derivados heterocìclicos de flúor-glicosìdeo, medicamentos contendo estes compostos e seu uso
BR0112224A (pt) Composto, composição farmacêutica, uso de um composto ou de um sal, solvato ou pró-droga farmaceuticamente aceitável do mesmo, e, processo para preparar um composto
BR0316605A (pt) Derivados de fluorglicosìdeos aromáticos, medicamentos contendo estes compostos e sua aplicação
BRPI0417458A (pt) compostos inibidores de dpp-iv, sais faramaceuticamente aceitáveis e pró-fármacos do mesmo, seus processos de preparação, composição farmacêutica compreendendo os mesmos e uso dos referidos compostos na fabricação de medicamento
BRPI0112986B8 (pt) compostos azabicíclicos, processo para a sua preparação, bem como composições farmacêuticas compreendendo os ditos compostos
BR0116322A (pt) Derivados de difenilazetidinona, processo para sua preparação, medicamentos contendo esses compostos e seu emprego
BRPI0606326A2 (pt) n-aminometileno sulfonamidas substituìdas, produção e uso das mesmas como medicamentos
CA2257328A1 (en) Thiazole derivatives
AR023058A1 (es) Derivados del tiazol, un procedimiento para su obtencion, composiciones farmaceuticas que los comprenden y el empleo de los mismos para la preparacion demedicamentos
WO2001058893A3 (de) Indol-3-yl-derivate und deren verwendung als integrin-inhibitoren
BRPI0607214B8 (pt) derivados de 2-(4-cianofenilamino)pirimidina inibidores de hiv, composição farmacêutica que os compreende e seus processos de preparação
AR022423A1 (es) Compuestos derivados de acidos 2,3,4,5-tetrahidro-1h-[1,4]benzodiazepina-3-hidroxamicos, composicion farmaceutica que los comprenden, y el uso de losmismos para la manufactura de un medicamento
UY26371A1 (es) Imidazo-3-il-aminas biciclicas, procedimiento para su preparacion y medicamentos que las contienen
UY31544A1 (es) Compuestos que potencian el receptor de ampa y usos de los mismos en medicina
BR0309668A (pt) Imidazolinilmetil aralquilsulfonamidas
DK1663970T3 (da) Matrixmetalloproteinaseinhibitorer
AR022542A1 (es) Derivados de piperidina y piperazina
DE69813263D1 (de) Hydrazono-benzazulen-derivate, pharmazeutische zusammensetzungen und zwischenprodukte
BR0311245A (pt) Fosfonatos e seus derivados como realçadores da atividade de inseticidas
AR090619A2 (es) Uso de un compuesto de tiazol para la produccion de un medicamento
BRPI0508925A (pt) derivados de éter, produção e uso deles como agentes farmacêuticos

Legal Events

Date Code Title Description
FA Abandonment or withdrawal